Key Highlights: Implications: Piramal Pharma’s move to 74% ownership of Yapan Bio for ₹76 crore turns the Hyderabad CDMO into a subsidiary, giving Piramal tighter control over Yapan’s process developm...
Key Highlights: Implications: Optimus Pharma’s DCGI approval for Tapinarof Cream 1% gives India its first locally manufactured, non‑steroidal topical for adult plaque psoriasis, offering dermatologist...
Elephas Biosciences, Neuberg Partner on Immuno-therapy Testing The Story: Elephas Biosciences has partnered with Neuberg Diagnostics to bring its elive live-tissue platform to India, with a clinical t...
Key Highlights: Implications: Biodeal’s ₹385 crore raise gives it the capital to scale up manufacturing, add new products, and enter more regulated markets, which should help it win bigger, longer-ter...
Key Highlights: Implications: If completed, the transaction would likely be a strong validation event for mid-sized Indian pharmaceutical businesses that combine branded generics, nu...
Key Highlights: Implications: RPG Life Sciences is launching India’s first fixed-dose Naproxen + Esomeprazole tablet, Naprosyn ES, to enable safer long-term NSAID use by adding gastroprote...
Key Highlights: Implications: Viatris is selling up to 92 million Biocon shares (about 5.6% of the company) in a secondary sale, so Biocon gets no money from it; the deal is priced at a di...
Key Highlights: Implications: The slump sale of Gennova’s small mRNA unit to Immunoscript for ₹139.5 crore effectively exits Emcure from a non-core, low-contribution bu...
Key Highlights: Implications: Mankind Pharma’s AI-led drug discovery partnership with Denovo Sciences strengthens its innovation agenda and adds another serious player to India’s eme...
Key Highlights: Implications: Sun Pharma’s acquisition of Innovcare looks like a portfolio-building move in India: for about ₹271.2 crore, Sun is buying a growing busin...
